ArticleCancers2025

Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer.

Tomoyuki Makino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.